Why J&J thinks its new psoriasis pill could be one of its biggest drugs ever

Johnson & Johnson is counting on its newly launched psoriasis pill to become its next cash cow. Investors want to know if it can live up to the hype. Icotyde went to market after the Food and Drug Administration approved it in mid-March for moderate to severe plaque psoriasis. The once-a-day drug is the first and only oral treatment targeting the same IL-23 receptor as popular injectables, including J & J's Tremfya, which is also indicated for psoriatic arthritis, ulcerative colitis, and …